If your institution subscribes to this resource, and you don't have an Access Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.
Download the Access App here: iOS and Android. Learn more here!
Vizimpro155,156,#
Antineoplastic, epidermal growth factor receptor (EGFR) family kinase inhibitor
EGFR-positive (exon 19 deletion or exon 21 L858R substitutions) non-small cell lung cancer (NSCLC)†
Afatinib, gefitinib, erlotinib, osimertinib
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Inhibitors of Epidermal Growth Factor Receptor (EGFR) Function
eChapter 2018: The Goodman & Gilman Year in Review New and Noteworthy FDA Approvals